EP Patent

EP2915525A1 — Sublingual abuse-resistant tablets comprising buprenorphine and naloxone

Assigned to Orexo AB · Expires 2015-09-09 · 11y expired

What this patent protects

There is provided a tablet suitable for sublingual administration comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof; particles of a pharmacologically-effective amount of naloxone or a pharmaceutically…

USPTO Abstract

There is provided a tablet suitable for sublingual administration comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof; particles of a pharmacologically-effective amount of naloxone or a pharmaceutically-acceptable salt thereof; a disintegrant; and particles of a weak acid provided in a sufficient amount to enable the provision of a pH of between about 4.0 and about 6.5 and maintenance of pH within that range for no more than about 3 minutes after administration to a patient.

Drugs covered by this patent

Patent Metadata

Patent number
EP2915525A1
Jurisdiction
EP
Classification
—
Expires
2015-09-09
Drug substance claim
No
Drug product claim
No
Assignee
Orexo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.